Patents Assigned to Yeda Research and Development
  • Publication number: 20210046271
    Abstract: A nasal cannula includes a prong formed from an inner cylindrical wall surrounded by an outer cylindrical wall, a base connecting the inner cylindrical wall to the outer cylindrical wall and an air channel formed between the inner and outer cylindrical wall. The inner cylindrical wall defines a bore through which air may freely flow. The nasal cannula additional includes a connector fluidly connected to the air channel and configured to provide flow communication between the air channel and an external device connected to the connector.
    Type: Application
    Filed: October 29, 2020
    Publication date: February 18, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Noam SOBEL, Ethan LIVNE, Aharon WEISSBROD, Sagit SHUSHAN, Danielle Ricca HONIGSTEIN
  • Patent number: 10920192
    Abstract: Provided is an isolated human naive pluripotent stem cell (PSC), wherein: (i) when the naive PSC is a female PSC, then said naive female PSC has two unmethylated alleles of an X-inactive specific transcript (XIST) gene; and (ii) when said naive PSC is a male PSC, then said naive male PSC has an unmethylated allele of said XIST gene. Also provided is a culture medium which comprises an ERK1/2 inhibitor, a GSK3beta inhibitor, a p38 inhibitor, a JNK inhibitor, a STAT3 activator and at least one agent selected from the group consisting of: bFGF, TGFbeta 1, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor; or at least agent selected from the group consisting of: a TGFR inhibitor, a FGFR inhibitor, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: February 16, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yaqub Hanna, Noa Novershtern, Yoach Rais
  • Patent number: 10923230
    Abstract: Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: February 16, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Eran Segal, Eran Elinav
  • Publication number: 20210038166
    Abstract: A method of predicting likelihood for childhood obesity, comprises: obtaining a plurality of parameters, wherein at least a few of the parameters characterize an infant or toddler subject. A machine learning procedure trained for predicting likelihoods for childhood obesity is feed with the plurality of parameters. An output indicative of a likelihood that the infant or toddler subject is expected to develop childhood obesity is received from the procedure. The output is related non-linearly to the parameters.
    Type: Application
    Filed: August 5, 2020
    Publication date: February 11, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Eran SEGAL, Smadar SHILO, Hagai ROSSMAN
  • Publication number: 20210038740
    Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.
    Type: Application
    Filed: October 21, 2020
    Publication date: February 11, 2021
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Valery KRIZHANOVSKY, Yossi OVADYA
  • Publication number: 20210041455
    Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
    Type: Application
    Filed: October 27, 2020
    Publication date: February 11, 2021
    Applicants: Yeda Research and Development Co. Ltd., Universitätsklinikum Hamburg-Eppendorf
    Inventors: Eran OVADIA, Irun R. COHEN, Johannes HERKEL, Raanan MARGALIT, Meirav PEVSNER-FISCHER
  • Publication number: 20210031193
    Abstract: Methods of controlling biological processes by altering the electric field gradient in a test chamber are disclosed. A portion of a surface of the test chamber is attached to at least one immobilized component of the biological process. Microfluidic devices capable of same are also disclosed.
    Type: Application
    Filed: September 23, 2020
    Publication date: February 4, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Roy BAR-ZIV, Alexandra TAYAR, Shirley SHULMAN DAUBE, Yuval EFRATH, Michael LEVY
  • Publication number: 20210032645
    Abstract: Methods of targeted recombination between homologous chromosomes in the genome of a somatic plant cell are described herein, wherein the target site may be located within a region of euchromatin or a region of heterochromatin. These methods may be used to induce a somatic plant cell into using targeted recombination between homologous chromosomes leading to targeted crossover or gene conversion. Methods described utilize a preselected endogenous target site at a locus having polymorphic alleles on the homologous chromosomes. Target site loci disclosed include those within euchromatin and heterochromatin.
    Type: Application
    Filed: January 11, 2018
    Publication date: February 4, 2021
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Avraham A. LEVY, Cathy MELAMED-BESSUDO, Shdema FILLER-HAYUT
  • Publication number: 20210030856
    Abstract: The present invention pertains to a novel cell based tumor vaccine platform. The invention provides a method for modifying antigen presenting cells (APCs) to present both MHC class I and/or MHC class II peptides in context of improved peptide presentation protein complexes in order to increase activation of a patient's immune response. In this invention, an MHC II mRNA dendritic cell based vaccine platform was developed to activate CD4+T cells in patients and to enhance the anti-tumor response. The invariant chain (Ii) was modified and the semi-peptide CLIP was replaced with an MHCII binding peptide sequences of tumor associated antigens. These chimeric MHC II constructs are presented by APCs and induce proliferation of tumor specific CD4+T cells. The invention provides the constructs, proteins, nucleic acids, recombinant cells, as well as medical applications of these products.
    Type: Application
    Filed: March 26, 2019
    Publication date: February 4, 2021
    Applicants: Deutsches Krebsforschungszentrum Stiftung des Ă–ffentlichen Rechts, Yeda Research and Development Co., Ltd.
    Inventors: Rachel Lea Eisenbach, Esther Tzehoval, Gal Cafri, Adi Sharbi Yunger, Mareike Grees
  • Publication number: 20210015889
    Abstract: Methods of disrupting a biofilm and/or preventing formation of a biofilm are provided. Accordingly there is provided a method of reducing or preventing formation of a biofilm and/or disrupting a biofilm comprising contacting a biofilm-producing microorganism with a carbonic anhydrase inhibitor; a urease inhibitor; a Ca2+ ATPase inhibitor; a tlp activator; and/or a myo-inositol catabolism pathway activator. Also provided are articles of manufacture and methods of treating a medical condition in which disrupting a biofilm and/or preventing formation of same is beneficial and methods of predicting or increasing sensitivity to an anti-microbial agent.
    Type: Application
    Filed: September 29, 2020
    Publication date: January 21, 2021
    Applicants: Yeda Research and Development Co. Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Ilana KOLODKIN-GAL, Alona KEREN-PAZ, Eitan KEREM, Gideon ZAMIR, Dror KOLODKIN-GAL, Malena COHEN-CYMBERKNOH
  • Publication number: 20200397853
    Abstract: A method of treating a heart disease in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related polypeptide and a Copolymer 1-related peptide, thereby treating the heart disease.
    Type: Application
    Filed: September 9, 2020
    Publication date: December 24, 2020
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Eldad TZAHOR, Ruth ARNON, Rachel SARIG, Rina AHARONI, Kfir Baruch UMANSKY
  • Publication number: 20200392001
    Abstract: This invention is directed to compositions and films comprising hydroxyapatite with minute amounts of doped inorganic fullerene-like (IF) nanoparticles or doped inorganic nanotubes (INT); methods of preparation and uses thereof.
    Type: Application
    Filed: February 21, 2019
    Publication date: December 17, 2020
    Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD., HOLON ACADEMIC INSTITUTE OF TECHNOLOGY
    Inventors: Reshef TENNE, Hila SHALOM, Lev RAPOPORT
  • Publication number: 20200392203
    Abstract: A composition of matter comprising an isolated soluble polypeptide comprising an amino acid sequence of a Transferrin receptor protein 1 (TfR1) apical domain is disclosed, the soluble polypeptide being capable of binding an Arenavirus. A fusion protein comprising an amino acid sequence of a TfR1 apical domain and an amino acid sequence of IgG Fc, the fusion protein capable of binding an Arenavirus, is also disclosed.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 17, 2020
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Ron DISKIN, Hadas COHEN-DVASHI
  • Publication number: 20200390053
    Abstract: The present invention relates to key genes in the biosynthesis of steroidal alkaloids and saponins, including regulatory genes and enzyme-encoding genes, and to use thereof for altering the content of steroidal (glyco)alkaloids or phytosterols in plants. The present invention provides genetically modified plants or gene edited plants with altered content of steroidal (glyco)alkaloids, particularly to Solanaceous crop plants with reduced content of antinutritional steroidal glycoalkaloids and to the increase in phytosterols, including cholesterol or cholestanol in these plants. The present invention also provides methods of altering gene expression.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 17, 2020
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Asaph AHARONI, Prashant SONAWANE, Maxim ITKIN
  • Publication number: 20200378752
    Abstract: Methods, devices and apparatus for measuring expansion/contraction properties of a material are described.
    Type: Application
    Filed: January 19, 2017
    Publication date: December 3, 2020
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Igor LUBOMIRSKY, Guy LAZOVSKI
  • Publication number: 20200380960
    Abstract: A prosodic speech recognition engine configured to identify prosodic features and patterns in a speech continuum for the extraction of linguistic content including para-syntactic content, discourse function, information structure, meaning, and speaker sentiment.
    Type: Application
    Filed: November 26, 2018
    Publication date: December 3, 2020
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Elisha MOSES, Tirza BIRON, Dominik FRECHE, Daniel BAUM, Nadav MATALON, Netanel EHRMANN, Eyal WEINREB
  • Publication number: 20200382221
    Abstract: An optical bus for multi-core processing providing optical data transfer between cores through a single planar waveguide employing a variable-thickness, light-propagation layer having a progressively changing effective refractive index in accordance with lateral position within the light-propagation layer such that light emission from a single light emitter in communication with one core is focused on each of multiple photodetectors in communication with its respective processer core.
    Type: Application
    Filed: August 20, 2018
    Publication date: December 3, 2020
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
    Inventor: Ulf LEONHARDT
  • Publication number: 20200382100
    Abstract: This invention provides electromechanical resonators based on metal chalcogenide nanotubes. The invention further provides methods of fabrication of electromechanical resonators and methods of use of such electromechanical resonators.
    Type: Application
    Filed: December 27, 2017
    Publication date: December 3, 2020
    Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD., B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD.
    Inventors: Reshef TENNE, Ernesto JOSELEVICH, Yiftach DIVON, Roi LEVI, Assaf YAAKOBOVITZ, Dan YUDILEVICH
  • Patent number: 10849985
    Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: December 1, 2020
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Valery Krizhanovsky, Yossi Ovadya
  • Publication number: 20200368322
    Abstract: A method of treating a disease associated with intestinal barrier dysfunction in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which downregulates the amount of glucose in intestinal cells, with the proviso that the disease is not Diabetes or obesity. Other agents for treating diseases associated with intestinal barrier dysfunction are also disclosed.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 26, 2020
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Benjamin GEIGER, Eran ELINAV, Inna GROSHEVA